Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
May 17, 2024 07:00 ET
|
Chemomab Therapeutics
TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for...
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab reported on major progress in Q1 2024, including that it is on track to report Phase 2 PSC topline data at midyear 2024
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
May 08, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab has been granted another 180-day extension to regain compliance with the minimum bid price requirement in order to remain listed on Nasdaq.
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
May 02, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab CEO Adi Mor will present at the Aegis Virtual Conference on May 7 at 9:00am ET
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
April 24, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab will release its first quarter 2024 financial results and provide a corporate update on May 9, 2024.
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
April 18, 2024 07:00 ET
|
Chemomab Therapeutics
Peer-reviewed patient study validates Chemomab's CCL24 as a novel target linked to greater disease severity and higher mortality in systemic sclerosis
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
April 02, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab's KOL primary sclerosing cholangitis virtual event on April 10 at 10:00 AM ET will include physician & patient PSC experts & a live Q&A session.
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
March 25, 2024 07:06 ET
|
Chemomab Therapeutics
Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories.